Literature DB >> 11144437

Tissue transglutaminase is the target in both rodent and primate tissues for celiac disease-specific autoantibodies.

I R Korponay-Szabó1, S Sulkanen, T Halttunen, F Maurano, M Rossi, G Mazzarella, K Laurila, R Troncone, M Mäki.   

Abstract

BACKGROUND: Endomysial antibodies have recently been shown to react with tissue transglutaminase. This study was undertaken to investigate whether the tissue distribution of transglutaminase is also compatible with reticulin, jejunal, and fibroblast autoantibody binding patterns.
METHODS: Sera from patients with and without celiac disease, monoclonal tissue transglutaminase antibodies, and sera from mice parenterally immunized against commercially available tissue transglutaminase, transglutaminase complexed with gliadin, or gliadin were used in indirect immunofluorescence and double-staining studies using both rodent and primate tissues as substrates. Also, antibody competition, affinity chromatography, and potassium thiocyanate extraction studies were undertaken.
RESULTS: Tissue transglutaminase antibody binding patterns were identical with the extracellular binding patterns seen with celiac patient sera. Human umbilical cord-derived fibroblasts exhibited both cytoplasmic and extracellular matrix staining. Double staining with patients' sera and tissue transglutaminase antibodies showed complete overlapping. Tissue transglutaminase effectively absorbed reticulin-endomysial antibodies from celiac sera, and patients' sera blocked the staining of the monoclonal tissue transglutaminase antibodies. Potassium thiocyanate extraction abolished the staining patterns, but they were elicited again after readdition of tissue transglutaminase.
CONCLUSIONS: Reticulin, endomysial, and jejunal antibodies detect transglutaminase in both rodent and primate tissues, indicating that these tissue autoantibodies are identical.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144437     DOI: 10.1097/00005176-200011000-00013

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  16 in total

Review 1.  Antibodies in celiac disease: implications beyond diagnostics.

Authors:  Sergio Caja; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

2.  Oral manifestations of coeliac disease.: A clinical-statistic study.

Authors:  M Costacurta; P Maturo; M Bartolino; R Docimo
Journal:  Oral Implantol (Rome)       Date:  2010-11-19

3.  Recurrent ischemic strokes in a young celiac woman with MTHFR gene mutation.

Authors:  Elisa Fabbri; Lisa Rustignoli; Antonio Muscari; Giovanni M Puddu; Maria Guarino; Rita Rinaldi; Elena Minguzzi; Giacomo Caio; Marco Zoli; Umberto Volta
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

4.  Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998.

Authors:  Marie-Hélène Metzger; Margit Heier; Markku Mäki; Enzo Bravi; Andrea Schneider; Hannelore Löwel; Thomas Illig; Detlef Schuppan; Heinz-Erich Wichmann
Journal:  Eur J Epidemiol       Date:  2006-04-29       Impact factor: 8.082

5.  Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits.

Authors:  T T Salmi; P Collin; I R Korponay-Szabó; K Laurila; J Partanen; H Huhtala; R Király; L Lorand; T Reunala; M Mäki; K Kaukinen
Journal:  Gut       Date:  2006-03-29       Impact factor: 23.059

6.  In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies.

Authors:  I R Korponay-Szabó; T Halttunen; Z Szalai; K Laurila; R Király; J B Kovács; L Fésüs; M Mäki
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Visualization of transepithelial passage of the immunogenic 33-residue peptide from alpha-2 gliadin in gluten-sensitive macaques.

Authors:  Kaushiki Mazumdar; Xavier Alvarez; Juan T Borda; Jason Dufour; Edith Martin; Michael T Bethune; Chaitan Khosla; Karol Sestak
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

8.  Screening for celiac disease in non-Hodgkin's lymphoma patients: a serum anti-transglutaminase-based approach.

Authors:  Antonio Carroccio; Emilio Iannitto; Lidia Di Prima; Sonia Cirrincione; Riccardo Troncone; Franco Paparo; Lydia Gianni Trapani; Antonio Gucciardi; Maurizio R Averna; Giuseppe Montalto; Alberto Notarbartolo
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

Review 9.  Transglutaminase 2 inhibitors and their therapeutic role in disease states.

Authors:  Matthew Siegel; Chaitan Khosla
Journal:  Pharmacol Ther       Date:  2007-05-13       Impact factor: 12.310

10.  Injection of celiac disease patient sera or immunoglobulins to mice reproduces a condition mimicking early developing celiac disease.

Authors:  Suvi Kalliokoski; Sergio Caja; Rafael Frias; Kaija Laurila; Outi Koskinen; Onni Niemelä; Markku Mäki; Katri Kaukinen; Ilma R Korponay-Szabó; Katri Lindfors
Journal:  J Mol Med (Berl)       Date:  2014-09-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.